Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An announcement from Cynata Therapeutics Limited ( (AU:CYP) ) is now available.
Cynata Therapeutics Limited will host an investor webinar led by CEO Dr. Kilian Kelly to engage with shareholders. The company’s ongoing clinical trials include a Phase 2 trial of CYP-001 for GvHD, a Phase 1/2 trial for kidney transplant patients, and a Phase 3 trial for osteoarthritis, highlighting their commitment to advancing their cell therapeutics pipeline.
More about Cynata Therapeutics Limited
Cynata Therapeutics Limited is an Australian clinical-stage biotechnology company focusing on stem cell and regenerative medicine. They develop therapies using their proprietary Cymerus™ platform technology, which utilizes induced pluripotent stem cells and mesenchymoangioblasts to produce cell therapy products economically at a commercial scale.
YTD Price Performance: -27.37%
Average Trading Volume: 3,300
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $33.2M
For a thorough assessment of CYP stock, go to TipRanks’ Stock Analysis page.
